ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Proteogenomic Profiling of Idiopathic Pulmonary Arterial Hypertension Identifies Sex-Differential Proteins and Candidate Therapeutic Targets.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundCurrent biomarkers for idiopathic pulmonary arterial hypertension (IPAH) lack disease specificity and provide limited biological insight. We hypothesized that integrating population-based proteomics with genetic evidence would identify robust IPAH-associated proteins relevant to risk stratification, early detection, prognosis, sex differences, and candidate drug-repurposing opportunities.
methodsWe analyzed 2,918 plasma proteins in 44,137 predominantly European-ancestry UK Biobank participants aged 40-69 years, including 252 incident and 141 prevalent IPAH cases. Proteins associated with IPAH were identified using Cox and logistic regression analyses, prioritized by cis-Mendelian randomization, and assessed through cross-ancestry effect-direction concordance and sensitivity analyses. Unsupervised clustering, nested cross-validated prediction models, and target-drug annotation were used for downstream evaluation.
resultsEighteen proteins showed convergent epidemiological and genetic evidence, and 12 remained supported in cross-ancestry and sensitivity analyses. These proteins defined a high-mortality endotype characterized by vascular and ventricular remodeling. Combined clinical and proteomic models achieved AUCs of 0.779 for incident IPAH and 0.768 for mortality. Proteomic contributions differed by sex, and target-drug annotation identified six drug-linked proteins, highlighting ANXA2-linked Artenimol as a repurposing candidate.
conclusionsTwelve biologically plausible IPAH-associated proteins inform risk stratification, prediction, sex-related characterization, and therapeutic prioritization. Independent multi-ancestry validation and mechanistic studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.